Handful of biotechs expected to IPO this fall, but many are stuck in ‘holding pattern’ until 2024

A pair of late-stage biotechs submitted IPO plans last week as industry insiders gear up for what could be a handful of post-Labor Day public debut pitches.

To repeat: That’s a handful of IPOs, not an overflowing basket of filings like the days of 2021 that saw at least 100…
Click here to view original post